In the presence of dsDNA, serum reactivity against DNase1L3 was variable affecting from 0% to 70% antibody binding (Fig. 6g), which is consistent with clinical data suggesting the presence of autoantibodies with mono and dual specificity to dsDNA and DNase1L3 in patients with SLE. The gene discussed is DNASE1L3; the disease is systemic lupus erythematosus.